ENTX Entera Bio Ltd.
Price Chart
Executive Summary
Entera Bio announced that multiple abstracts across its oral peptide pipeline were accepted for ENDO 2026, with new clinical data supporting its EB613 osteoporosis candidate selected for a late-breaking oral presentation. This is a positive catalyst for a clinical-stage biotech because it validates the EB613 Phase 3 candidate selection with new data at a major medical conference, but no financial terms, approval decisions, or definitive guidance were provided.
Actionable Insight
Traders should watch for the EB613 late-breaking oral presentation at ENDO 2026 on June 14. Positive data readout could be a significant catalyst given Entera's ~$59M market cap and lack of approved products. Risk remains that data may underwhelm or that timelines shift.
Key Facts
- EB613 (oral PTH(1-34) for osteoporosis) new clinical data selected for Late Breaking Oral Presentation at ENDO 2026 (June 13-16, 2026).
- Abstract for EB613 titled 'Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study'.
- Pre-clinical results for EB612 (oral long-acting PTH(1-34) for hypoparathyroidism) and EB618 (oral dual GLP-1/glucagon agonist for obesity/metabolic disorders) also accepted.
- ENDO 2026 takes place June 13–16, 2026 in Chicago; EB613 late-breaking oral session is Sunday, June 14, 2026 at 3:30 PM CT.
- Entera is a clinical-stage company with no approved products; its most advanced candidate EB613 completed a Phase 2 study meeting primary and secondary endpoints.
Financial Impact
No financial data provided; market cap ~$59M. Positive pipeline milestone for early-stage biotech.
Risk Factors
- Clinical-stage company with no approved products — binary event risk around Phase 3 plans.
- Presentation is an abstract at a medical conference; data quality/impact unknown until release.
- Going concern and financing risk noted in forward-looking statements.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302886 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
17d ago
|
Press Release
| $1.22 $1.22 | · 0.00% | ▲ +0.05% | $1.23 (+0.82%) |
|
May 18, 2026
28d ago
|
EFFECT
| $1.23 $1.21 | ▼ −1.63% | ▼ −3.24% | $1.23 (+0.00%) |
|
May 8, 2026
5w ago
|
S-3
| $1.17 $1.23 | ▲ +5.13% | ▲ +5.21% | $1.23 (+5.13%) |
|
May 8, 2026
5w ago
|
8-K
| $1.17 $1.23 | ▲ +5.13% | ▲ +5.21% | $1.23 (+5.13%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $1.13 $1.19 | ▲ +5.31% | ▲ +3.92% | $1.23 (+8.85%) |
|
Apr 3, 2026
10w ago
|
8-K
| $1.19 $1.12 | ▲ +5.88% | ▲ +10.02% | $1.23 (−3.36%) |
|
Apr 2, 2026
10w ago
|
Press Release
| $1.26 $1.15 | ▼ −8.73% | ▼ −12.35% | $1.23 (−2.38%) |
|
Mar 27, 2026
11w ago
|
Press Release
| $1.00 $1.17 | ▲ +17.00% | ▲ +12.70% | $1.23 (+23.00%) |
|
Mar 5, 2026
14w ago
|
Insider Cluster
| $1.23 $1.32 | ▲ +7.32% | ▲ +9.55% | $1.23 (+0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access